Ivantis is developing the Hydrus Microstent, a minimally invasive implant designed to dilate and scaffold the natural outflow path of the eye to treat glaucoma. It has raised $107 million and conducted clinical trials involving over 2,000 patients in 21 countries. A recent randomized controlled trial found that 74% of patients who received the Hydrus Microstent in addition to cataract surgery experienced at least a 20% reduction in eye pressure without medication, compared to 46% for cataract surgery alone, demonstrating the Hydrus' increasing treatment effect over time. Ivantis is pursuing US FDA approval for the Hydrus Microstent based on these promising clinical results.

1. Ivantis Overview
David Van Meter
OIS @ ASCRS
April 16, 2015
Investigational Device Only in US 1

2. Ivantis Overview
• Founded 2007 by top coronary stent inventors
• Developing a minimally invasive microstent for glaucoma
that dilates and scaffolds the natural outflow path of the eye
• 27 FTE’s; based in Irvine, CA
• $107 MM raised to date ($71 MM B round closed last year)
• Global investor syndicate lead by NEA and Delphi
• Over 2,000 patients treated globally
• 21 countries and 75 surgeons
• All patients either in Level One RCT’s or Global “Real
World” Registry
• Just completed recruitment in 558 subject US pivotal trial
Investigational Device Only in US 2

3. The Hydrus™ Microstent
Flexible, biocompatible
Schlemm’s canal
“scaffold”
Scalloped and open
design allows aqueous
flow
3 clock-hour length
targets multiple collector
channels
** Investigational
Device Only in
USA
3

4. Hydrus Surgical Video
Investigational Device Only in US 4

5. Commitment to Basic Science
5
Toris, Samuelson, Ahmed et al Outflow
IOVS 2013:54:1698-1704
Grierson,
Kahook, et al
3 month Monkey
Biocompatibility
Study
J Glaucoma
Nov 2013 ePub
ahead of printGong, Johnstone, et al. Fluorescent
Dye Intensity Study (AGS Paper 2013)
Johnstone,
Samuelson, et al
Collector
Channel
Preservation
Study
Experimental
Eye Research
2014;119:70-76
Investigational Device Only in US

6. Investigational Device Only in US 6
HYDRUS II Study
A Prospective, Multicenter, Controlled, Randomized Trial
Comparing Hydrus + Cataract to Cataract Alone
In Press: Ophthalmology
Top 10 Paper: AGS 2015

7. HYDRUS II:
Level One Clinical Evidence
• Trial was designed to closely simulate US pivotal trial
– Utilizes the “state of the art” study design standards utilized in
current FDA MIGS trials
– Medications removed (“washout”) prior to surgery and 1 and 2 year
follow-ups to remove confounding effect of medications on IOP
• 7 top EU academic centers (Norbert Pfeiffer, PI)
• 100 eyes with mild to moderate OAG undergoing cataract
surgery
• 1:1 randomization day of surgery
• Average patient entered study at IOP of 19 on 2 meds;
washout IOP was 26.5
77Investigational Device Only in US

8. HYDRUS II: Results
100.0%
84.0% 83.7%
77.1%
83.3%
72.9%
47.9% 46.9%
50.0%
37.8%
0%
20%
40%
60%
80%
100%
Baseline 1M 6M 12M 18M 24M
%ofPatients
Medication Free Patients
Hydrus+CS CS
3 of 4 of Hydrus patients
vs. 1 of 3 cataract surgery
remain medication free
at 2 years
P=0.0008
Investigational Device Only in US 8

9. T R E AT M E N T R E S P O N S E
Investigational Device Only in US
9
88%
80%
74%
46%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
12 Months 24 Months
HYDRUS II: 20% Drop in Washed Out Diurnal IOP
Hydrus Control
Analysis conducted on intention-to-treat basis.
(N=50) (N=50) (N=50) (N=50)
= 34%
P = 0.0008
Hydrus
increases
response by
74% compared
to cataract
surgery alone
HYDRUS II: Results

10. Ivantis Summary
• Strong pre-clinical foundation through extensive
basic science
• Emphasis on Level One Clinical Evidence (multi
center RCT’s)
• Demonstrating an increasing effect over time relative
to control group in Level One Clinical Trial
• Global clinical experience in wide array of indications
(not just mild glaucoma with cataract)
• Well funded and now pursuing US FDA approval
Investigational Device Only in US 10